Globus Medical (GMED) Q2 2025 earnings summary

Executive summary

• Q2 2025 net sales reached $745.3 million, up 18.4% year-over-year, driven by the Nevro acquisition and strong musculoskeletal solutions growth.

• GAAP net income surged to $202.8 million, supported by a $110.6 million bargain purchase gain and a $34.8 million tax benefit.

• Leadership transition completed with Keith Pfeil promoted to CEO and Kyle Kline to CFO, emphasizing continuity and internal strength.

• Strategic focus on integrating recent acquisitions and accelerating product innovation to drive organic growth.

• Company mission remains centered on improving musculoskeletal care with financial discipline and operational excellence.

Financial highlights

• Q2 2025 revenue: $745.3 million (+18.4% year-over-year); non-GAAP EPS was $0.86, up 14.1%.

• GAAP net income was $202.8 million, including a $110.6 million bargain purchase gain and $28.8 million in M&A costs.

• Free cash flow was $31.3 million; operating cash flow for H1 2025 was $255.2 million, up $148.5 million year-over-year.

• Adjusted EBITDA margin for the base business was 32.3%, with overall Q2 adjusted EBITDA at $208.7 million (28.0% of net sales).

• Gross profit margin was 67.4% non-GAAP and 63.3% GAAP for Q2 2025.

Outlook and guidance

• 2025 net sales guidance reaffirmed at $2.8–$2.9 billion; non-GAAP EPS guidance of $3.00–$3.30.

• Full-year non-GAAP tax rate expected to be approximately 25%.

• Management expects continued integration of Nevro and realization of synergies from recent acquisitions.

• The company is evaluating the impact of the One Big Beautiful Bill Act, signed in July 2025, on future tax positions.

• Management remains confident in U.S. spine and enabling tech growth, with international growth expected to improve as integration progresses.